Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: A non-randomized, non-controlled study

Current Medical Research and Opinion

Volumn 23, Issue 6, 2007, Pages 1269-1278

  Ponseti, José M ^a   Gamez, Josep ^a   Azem, Jamal ^a   Fort, José M ^a   López Cano, Manuel ^a   Vilallonga, Ramon ^a   Buera, Martín ^a   Armengol, Manuel ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cholinergic receptors; Immunosuppressive agents; Myasthenia gravis; Neuromuscular junction; Prednisone; Remission; Tacrolimus (FK506); Thymectomy

Indexed keywords

IMMUNOGLOBULIN; PREDNISONE; TACROLIMUS;

ACNE; ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CUSHINGOID HABIT; CUSHINGOID SYNDROME; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EDEMA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOMAGNESEMIA; MALE; MONOTHERAPY; MUSCLE CRAMP; MYASTHENIA GRAVIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PARESTHESIA; REMISSION; SIDE EFFECT; THYMECTOMY; TREMOR;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LENGTH OF STAY; MALE; MIDDLE AGED; MUSCLE STRENGTH; MYASTHENIA GRAVIS; PREDNISONE; REMISSION INDUCTION; TACROLIMUS; THYMECTOMY; TIME FACTORS;

EID: 34347270160     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X188080     Document Type: Article

References (27)

1. Blalock A, Harvey A, Ford F, Lilienthal J Jr. The treatment of myasthenia gravis by removal of the thymus gland. JAMA 1941;117:1529-1531
2. Thanvi BR, Lo TC. Update on myasthenia gravis. Postgrad Med J 2004;80:690-700
3. Onodera H. The role of thymus in the pathogenesis of myasthenia gravis. Tohoku J Exp Med 2005;207:87-98
4. Jaretzki A, Steinglass KM, Sonett JR. Thymectomy in the management of myasthenia gravis. Semin Neurol 2004;24:49-62
5. Gronseth GS, Barohn RJ. Thymectomy for myasthenia gravis. Curr Treat Options Neurol 2002;4:203-9
6. Sieb JP. Myasthenia gravis: emerging new therapy options. Curr Opin Pharmacol 2005;5:303-7
7. Ciafaloni E. Mycophenolate mofetil and myasthenia gravis. Lupus 2005;14(Suppl 1):S46-9
8. Ponseti JM, Azem J, Fort JM, Codina A, et al. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. Clin Neurol Neurosurg 2005;107:187-90
9. Ponseti JM, Azem J, Fort JM, Lopez-Cano M, et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 2005;64:1641-3
10. Ponseti JM, Azem J, Fort JM, López-Cano M, et al. Experience with starting tacrolimus postoperatively after extended transsternal thymectomy in patients with myasthenia gravis. Curr Med Res Opin 2006;22:885-95
11. Masaoka A, Yamakawa Y, Niwa H, Fukai I, et al. Extended thymectomy for myasthenia gravis patients: a 20-year review. Ann Thorac Surg 1996;62:853-9
12. López-Cano M, Ponseti-Bosch JM, Espin-Basany E, Sánchez-García JL, et al. Clinical and pathologic predictors of outcome in thymoma-associated myasthenia gravis. Ann Thorac Surg 2003;76:1643-9
13. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, et al. Myasthenia gravis: recommendations for clinical research standards [Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America]. Neurology 2000;55:16-23
14. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-92
15. Ponseti JM. Miastenia gravis. Manual terapeutico. Barcelona: Springer Verlag, 1995
16. Huang CS, Hsu HS, Huang BS, Lee HC, et al. Factors influencing the outcome of transsternal thymectomy for myasthenia gravis. Acta Neurol Scand 2005;112:108-14
17. Budde JM, Morris CD, Gal AA, Mansour KA, et al. Predictors of outcome in thymectomy for myasthenia gravis. Ann Thorac Surg 2001;72:197-202
18. Kattach H, Anastasiadis K, Cleuziou J, Buckley C, et al. Transsternal thymectomy for myasthenia gravis: surgical outcome. Ann Thorac Surg 2006;81:305-8
19. Sekine Y, Kawaguchi N, Hamada C, Sekiguchi H, et al. Does perioperative high-dose prednisolone have clinical benefits for generalized myasthenia gravis? Eur J Cardiothorac Surg 2006;29:908-13
20. Antin JH, Kim HT, Cutler C, Ho VT, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003;102:1601-5
21. Timerman AP, Ogubumni E, Freund E, Wiederrecht G, et al. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. J Biol Chem 1993;268:22992-9
22. Mayrleitner M, Timerman AP, Wiederrecht G, Fleischer S. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506 binding protein: effect of FKBP-12 on single channel activity of the skeletal muscle ryanodine receptor. Cell Calcium 1994;15:99-108
23. Nemoto Y, Kuwabara S, Misawa S, Kawaguchi N, et al. Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry 2005;76:714-18
24. Mygland A, Aarli JA, Matre R, Gilhus NE. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiatry 1994;57:843-6
25. Takamori M, Motomura M, Kawaguchi N, Nemoto Y, et al. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 2004;62:1894-6
26. Davies TH, Ning YM, Sánchez ER. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 2005;44:2030-8
27. Dal Belo CA, Leite GB, Fontana MD, Corrado AP, et al. New evidence for a presynaptic action of prednisolone at neuromuscular junctions. Muscle Nerve 2002;26:37-43